Goal: To evaluate the potential role of the determination of the immunocomplexed form of squamous cell carcinoma antigen [SCCA-immunoglobulin (Ig)M] for the screening of Barrett esophagus (BE) and esophageal adenocarcinoma (EAC).
T he prevalence of Barrett esophagus (BE) in patients undergoing endoscopy for gastroesophageal reflux disease (GERD) is highly variable, 1-5 the cost-effectiveness of screening is high and the international guidelines identify well-defined subgroups of patients only in whom screening might be cost-effective. [6] [7] [8] The real risk of esophageal adenocarcinoma (EAC) in patients with BE is still debated and a meta-analysis 9 indicates an annual incidence <0.5%, a figure in any case lower than previously assumed 10 suggesting that the risk of EAC in patients with BE has been overestimated. [11] [12] [13] [14] When diagnosed in patients undergoing surveillance for BE, EAC is in an earlier stage 15 but the impact of surveillance on survival is modest 16, 17 and the life expectancy of patients with BE is not significantly different from that of the general population, 18 with a risk, albeit low, of complications of the endoscopic and surgical procedures. 15 Overall, it is recognized that patients with dysplasia 10, 19 or long segment BE (LSBE) [20] [21] [22] [23] are at higher risk for EAC and should be followed up more strictly. 7 On these premises, biomarkers efficient in singling outpatients with GERD requiring endoscopic and bioptic screening and BE at higher risk of EAC who should undergo routine surveillance are eagerly awaited. Intraepithelial neoplasia (lEN, according to the WHO recent definition, formerly dysplasia) is the only biomarker that can be proposed for routine clinical use, [24] [25] [26] with the hope of improving the screening cost-effectiveness. 27 IEN is indeed the only biomarker that reached the phase IV of the National Cancer Institute's Early Detection Research Network (EDRN) algorithm for a biomarker validation 28, 29 (Table 1) . Unfortunately, IEN (as any other tissue marker) requires endoscopy and bioptic sampling to identify patients at risk, while the availability of a circulating serum biomarker would dramatically simplify the approach to cancer screening in patients with GERD and to surveillance in patients with BE. However, such a marker simply does not exist.
Squamous cell carcinoma antigen (SCCA) is a member of the serine-protease inhibitors (serpins), first isolated by Kato and Torigoe 30 in cervix cancer in 1977. The serine protease inhibitors share similar structure, intracellular and extracellular localization and mechanisms of activity, each acting on specific proteases. 31 Two distinct genes have been identified on chromosome 18q21.3 that code for SCCA1 (the "neutral" form, ie, SERPINB3), which inhibits various cathepsins and SCCA2 (the "acid" form, ie, SERPINB4), that inhibits cathepsin G and mast-cell chymase. 32, 33 SCCA isoforms are detectable in various squamous epithelia and squamous cell tumors and increased serum levels have been documented in patients with head and neck, lung, mammary and esophageal cancers, [34] [35] [36] [37] [38] [39] [40] as well as in neoplastic, nonsquamous, cells of epithelial origin. 41 Previous works by our research group demonstrated SCCA expression also in hepatocellular carcinoma. 42 Both SCCA1 and SCCA2 are involved in tumor development by inhibiting apoptotic cell death. SCCA1 shows a specific role in modulating tumor growth and metastasis and, in particular, in the epithelium to mesenchymal transition, 43 but is expressed even in the early stages of carcinogenesis, as demonstrated in liver cancer. 44 The determination of the immunocomplexed form of SCCA [SCCA-immunoglobulin (Ig)M] increases the sensitivity of the assay. 45 With respect to esophageal cancer, increased serum SCCA levels have been demonstrated in squamous cell carcinoma. 46 So far studies using reverse transcription polymerase chain reaction or immunohistochemistry reported conflicting results on the expression of SCCA in different dysplastic or neoplastic lesions. 45, 47 Our study was aimed at assessing the potential role of serum SCCA-IgM determination in screening and surveillance of BE and in EAC, for a noninvasive identification of patients at higher risk for EAC in a phase III study.
PATIENTS AND METHODS
The study was performed in 231 patients, prospectively recruited and undergoing upper gastrointestinal endoscopy in the out-patient clinic of the Gastroenterology Section or surgery for esophageal cancer in the Surgical Section of the Department of Surgery, Oncology and Gastroenterology of Padua University Hospital. The patients were subgrouped as follows:
patients with previously diagnosed BE undergoing routine follow-up endoscopy: 71 samples, 18 of which, deriving from patients with additional known synchronous or recent malignancies, were excluded from the analysis (53 samples); EAC: 53 samples; these patients were arbitrarily subgrouped in "early stage" (stages 0-1-2, ie, those with direct surgical indication) and "advanced stage" (stages 3-4, ie, those who underwent neoadjuvant treatment before surgery or did not undergo surgery at all); controls: 107 samples including 42 blood donors and 65 consecutive patients with GERD but with endoscopy and histology excluding a diagnosis of BE (GERD). Because of the exclusion of the above 18 samples, the final number of patients recruited for our study was 213.
All samples were collected following the patients' informed consent. The diagnosis of BE was based on the execution of routine biopsies according to the Seattle protocol 48 and obtained by expert gastrointestinal pathologists in the frame of the EBRA registry 49 (the North-Eastern Italian Registry for the management of BE). The Prague classification was used to define BE staging 50 and patients were considered "at risk" on the basis of the more recent guidelines. lEN was classified according to the WHO. 25, 26 Serological SCCA-IgM SCCA serum levels were quantified using the determination of the immunocomplex SCCA-IgM, with an ELISA Kit (Hepa-IC; Xeptagen Spa, Marghera, Venice, Italy).
In brief, the serum samples were diluted and incubated with anti-SCCA antibodies. SCCA-IgM immunocomplexes were determined by adding an antibody conjugated with an enzyme specific for human IgM. SCCA-IgM levels are expressed in U/mL.
Tissue SCCA Expression
To confirm the serum data, a subgroup of BE and GERD patients was studied for SCCA tissue expression by immunohistochemistry. The group included:
35 consecutive cases of histologically proven BE; 20 patients with a long history of GERD-compatible symptoms (> 1 y) with cardiac-type esophageal metaplasia at histology; 20 GERD patients with no histologic alterations (ie, naive esophageal mucosa). SCCA immunostaining was done using a rabbit polyclonal antibody (Hepa-Ab; Xeptagen Spa) on the automated Leica Microsystems Bondmax (Leica, Wetzlar, Germany). Immunostaining was jointly scored by 2 pathologists (M.F. and M.R.). Both cytoplasmic and nuclear staining was retained for scoring. Immunostaining was semiquantified using a 3-tier scoring system based on the intensity of staining (0 = negative; 1 = weak/moderate; 2 = strong).
Statistical Analysis
On the basis of the results of a preliminary Kolmogorov-Smirnov test, the Mann-Whitney U, the Kruskall-Wallis and w 2 tests were used. Cutoffs were calculated by using the receiver operating characteristic (ROC) curve method. A 2-tailed P < 0.05 was held as significant. Statistics were performed using the STATSDIRECT and the PAWS Statistics 18 software.
RESULTS
The features of BE, EAC, and GERD patients are reported in Tables 2-4 . BE patients were mostly male (81%), with hiatal hernia (81%) and with conditions "at risk" such as LSBE or IEN in 28% and 30% of the cases, respectively. LSBE was associated with IEN in 3 patients (20%). EAC patients were again mostly male (83%) and with an "advanced stage" disease (stage 3-4) in slightly over half of the cases (53%).
Serum SCCA-IgM levels were not normally distributed. We first evaluated serum SCCA-IgM levels in blood donors and GERD patients: no statistically significant difference in the median SCCA-IgM values was observed [41.5; 95% confidence interval (CI), 49.37-91.33 and 36.6; 95% CI, 40.32-68.28, respectively). Despite this, only the patients in the GERD group were eventually used as controls. When GERD patients were compared with BE and EAC by using a Kruskall-Wallis test, a significant trend was observed (P < 0.0001). Table 5 depicts the median serum levels of SCCA-IgM in BE and EAC patients as compared with GERD. The difference between BE, EAC, and BE + EAC versus GERD was highly statistically significant (P < 0.0001) for all comparisons. The cutoff for SCCA-IgM, as calculated by the ROC curves between patients affected by either BE or EAC and GERD patients was 56.6 AU/mL with a 91.5% sensitivity, 75.4% specificity, a positive predictive value (PPV) of 85.8%, a negative predictive value (NPV) of 84.4% and an area under the curve (AUC) of 0.799. For a patient with values of SCCAIgM above this cutoff, the relative risk (RR) of harboring significant esophageal lesions (BE or EAC) was 33 (Fisher exact 95% CI, 12.66-89.46; P < 0.0001) (Fig. 1) .
With respect to BE patients, no statistically significant difference was documented between patients with LSBE and short segment BE (SSBE), presence or absence of IEN or of hiatal hernia (data not shown). However, when BE patients were stratified in those "at high risk" of neoplastic evolution (LSBE ± IEN or SSBE with IEN) (median value 92; 95% CI, 89.6-164.2) versus those "at low risk" (SSBE, no IEN) (median value 75; 95% CI, 69.2-107.3), a statistically significant difference was documented between the 2 subgroups (P < 0.035).
By using the ROC curve method, a cutoff to identify patients "at high risk" was calculated at the level of 78.5 U/ mL, AUC = 0.67 (95% CI, 0.51-0.83), PPV = 68%, NPV = 76%. With this cutoff 23/27 BE included in the subgroup "at high risk" were correctly diagnosed (sensitivity 85%) while 13/26 BE at low risk were also correctly identified (specificity 50%), with a likelihood ratio for BE patients having SCCA-IgM levels above the cutoff of belonging to the "high risk" group of 7.63 (Fisher exact 95% CI, 1.77-37.85; P = 0.003).
BE patients had higher SCCA-IgM levels than EAC patients (P < 0.005) and BE patients "at high risk" had SCCA-IgM serum levels significantly higher than patients with both low stage or advanced EAC (P < 0.05 and 0.009, respectively).
With respect to SCCA immunostaining, normal squamous epithelium showed a strong 2 + positivity in the supra-basal layers in all patients but was totally negative in the proliferative compartment. Cardiac epithelium was positive at 1 + level only in 3/20 patients while BE metaplasia was 1 + positive in 22/35 patients an 2 + in 1/35, for a total of 23/35 (66%). The difference between GERD with cardiac-type metaplasia and BE was statistically significant (P = 0.0003), while no significant difference in SCCA expression was observed with respect to the presence of IEN or in high risk BE (Fig. 2) .
DISCUSSION
The cost-effectiveness of screening for BE in patients with GERD is still debated [6] [7] [8] and not totally clear is even the cost-effectiveness of the surveillance in BE, where the risk of cancer has been probably overestimated for a long time. 10 Actually, several authors raise strong doubts on the point, taking into account the relatively low risk of cancer 14, 15 (with the exception of patients harboring IEN ), and the fact that these patients more frequently die of alternative causes, for instance of ischemic heart disease. 51 In addition, the invasiveness of the endoscopic surveillance, with extensive bioptic sampling, the potential risk of complications both during endoscopy and therapeutic (surgical or endoscopic) procedures, 52 and the limited impact in terms of quality of life adjusted life years 53 further hamper a positive balance between "costs" and results obtained.
In BE, as well as in any other neoplastic or preneoplastic disease, biomarkers might play several roles as diagnostic, predictive, and prognostic biomarkers. 54, 55 In screening patients affected by GERD for BE or EAC, a biomarker could help to identify patients with BE, single out those at higher risk of progression toward EAC and/or those potentially already harboring EAC. This could lead to a safer and less invasive endoscopic management and to a reduction in endoscopy-related costs and morbidity, conversely sorting out BE patients at minimal or absent risk of progression, in an attempt to reducing surveillance costs and patients' anxiety.
Among the many biomarkers proposed to identify BE patients at higher risk of cancer, only the detection of tissue findings such as noninvasive neoplasia, aneuploidy, and loss of heterozigosity reached EDRN stage IV, and only the presence of IEN is routinely assessed and modulates surveillance schedule and therapeutic choices. 29, 56, 57 Recently, Gordon et al, 27 using a Markov model, produced data that support the use of biomarkers in BE surveillance. What we really need indeed is a serum biomarker that could provide us with the answers to these very simple questions: has this GERD patient a substantial risk of harboring BE or EAC and is this BE patient at higher risk of progression toward IEN or EAC and should he therefore undergo a stricter surveillance?
In this experience, the first one dealing with SCCAIgM determination in BE patients serum samples, our marker seems to provide, at least in part, these 2 answers. Patients with BE and esophageal cancer presents significantly higher SCCA-IgM serum levels and the determination offers a 91.5% sensitivity, 75.4% specificity, 85.8% PPV, and 84.4% NPV. The RR of having a preneoplastic or a neoplastic esophageal lesion for a patient with levels of the marker above the cutoff is 33 times higher than that of patients with low SCCA-IgM levels.
In addition, when considering only BE patients, the marker allows, again with high sensitivity, the identification of the subgroup of patients who are at higher risk of cancer development, with a 8 times higher RR, due to the presence of LSBE and/or IEN, 6, 57 and should therefore be more accurately surveyed in time.
The relatively low specificity of the test may, in this scenario, represent a relevant issue and increase the costs of the screening but, given that patients with GERD will, sooner or later in their history, undergo an endoscopic procedure and that patients with BE routinely undergo surveillance at fixed time interval, the use of SCCA-IgM will in any case reduce the number of endoscopies performed with respect to those carried out without the use of the biomarker, thus reducing the relative costs.
Finally, BE patients, particularly when "at high risk", have SCCA-IgM levels higher than patients with EAC. From the biologic point of view, SCCA is deeply involved in both physiological and pathologic processes, and modulates several cancer-related mechanisms, such as apoptosis. 58 This is due to the interplay with factors leading to activation of caspase 3, and to epithelial-mesenchymal transition, a process induced by a down-regulation of E-cadherin and, conversely, an up-regulation of b-catenin C A B and vimentin. 43 SCCA role in both preneoplastic and neoplastic changes has been demonstrated in several types of cancer, with liver dysplastic nodules in cirrhosis demonstrating high levels of expression. 44 With respect to esophageal cancer, SCCA expression in preneoplastic changes has been described as increased 46 but in any case lower than in squamous cell carcinoma. 59 The results obtained in this experience with BE and EAC demonstrate that the serpin is involved in the development of EAC, as well as of its preneoplastic lesion and the behavior of this biomarker closely resembles what we have documented in the liver 44 with higher levels of the marker in preneoplastic lesions, namely dysplastic nodules, than in cancer. This suggests that, in esophageal as well as in liver cancer, the serpin is overexpressed in the early phases of carcinogenesis and apparently modulates progression to cancer more than invasion and metastasis.
The data we obtained by determining serum SCCAIgM levels were substantially confirmed by what observed for SCCA immunostaining. Normal squamous esophageal epithelium had a moderate to strong positivity but only in the maturative layers while the proliferative, basal one was negative. Similarly, cardiac-type columnar metaplasia was substantially negative. BE had a 1 + to 2 + positive staining in approximately two third of the cases. SCCA is usually expressed in the nonpathologic squamous esophageal epithelium, but only in the suprabasal and surface layers 47, 60 where it probably exerts a role in the regulation of the physiological squamous cell maturation and death. The cells in the superficial layer are most often lost by desquamation or esfoliation and very rarely go into apoptosis, thus limiting the amount of SCCA released in the circulation to negligible levels. In contrast, the expression of SCCA in the glands of BE epithelium is probably to refer to changes involved in their "premalignant" transformation, with a switch-on of serin proteases and of their inhibitors and an activation of epithelial-mesenchymal transition. 43 The detection of the SCCA immunocomplex in the serum of patients harboring BE and EAC is probably due to the accelerated cell turn-over that allows higher circulating levels of SCCA which, immunocomplexed with IgM, can be detected in serum.
In conclusion, SCCA-IgM determination could be used as a diagnostic biomarker to select the patients with GERD who need an earlier endoscopic assessment in BE screening and those with BE who could require a stricter endoscopic follow-up. In line with the EDRN positions, we are now proceeding to a validation of the role of SCCA IgM determination but the results obtained in this phase seem to be promising. Additional prospective studies of GERD patients and longitudinal studies based on a longterm follow-up of BE patients are required to confirm our findings, but SCCA-IgM could be the first serum biomarker apparently ready for a phase IV validation.
